Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer
Open Access
- 1 January 2013
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 41991
Abstract
Data from over 20 years ago demonstrated potential use for insulin-like growth factor (IGF) signaling modulators, specifically with IGF-1R antagonists, in a variety of pediatric and adolescent cancers, particularly in sarcomas. However, in spite of promising preclinical data, IGF-1R inhibitors have not had the success as single agents that was originally hoped for in clinical trials. Several potential mechanisms exist by which tumors are resistant to IGF-1R inhibitors. Notably, these resistance mechanisms are currently best understood in Ewing sarcoma and alveolar rhabdomyosarcoma. Various treatment schema have been proposed as a potential way to overcome this resistance. The use of IGF-1R inhibitors, mechanisms of resistance, and current ongoing clinical studies using IGF-1R inhibitors in pediatric cancers are reviewed here.Keywords
This publication has 69 references indexed in Scilit:
- Blastemal Expression of Type I Insulin-Like Growth Factor Receptor in Wilms' Tumors Is Driven by Increased Copy Number and Correlates with RelapseCancer Research, 2006
- Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialThe Lancet, 2006
- Insulin-Like Growth Factor-I Receptor Expression Regulates Neuroblastoma Metastasis to BoneCancer Research, 2006
- Insulin-Like Growth Factor I Receptor Pathway Inhibition by ADW742, Alone or in Combination with Imatinib, Doxorubicin, or Vincristine, Is a Novel Therapeutic Approach in Ewing TumorClinical Cancer Research, 2006
- IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1Oncogene, 2005
- Gastrointestinal Stromal Tumors in Children and Young AdultsJournal of Pediatric Hematology/Oncology, 2005
- Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype.1999
- Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice.1998
- Proteolysis of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in 150-kilodalton IGFBP complexes by a cation-dependent protease activity in adult rat serum promotes the release of bound IGF-I.Endocrinology, 1996
- Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth.1994